期刊文献+

盐酸伊伐布雷定对中国健康受试者的心率及QTc间期的影响 被引量:5

Impact of hydrochloride ivabradine on the heart rate and QTc interval of healthy Chinese volunteers
原文传递
导出
摘要 目的评价单次及连续服用盐酸伊伐布雷定对中国健康受试者心率及QTc间期的影响。方法36例受试者均分为3个剂量组,第1、8天单次口服相应剂量伊伐布雷定片5mg(低剂量组)、10mg(中剂量组)、20mg(高剂量组);第3~7天连续5d,每次口服伊伐布雷定片相应剂量5、10、20mg,每日2次。观察受试者心率、QTc间期的变化及不良事件的发生情况。结果单次服药后2h,3组受试者心率均较服药前下降[(62.67±5.68)次/min对(59.75±6.52)次/min,(67.00±7.11)次/min对(62.75+8.35)次/min,(65.58+9.16)0次/min对(56.50±3.92)7次/min];服药后6h,心率恢复至服药前水平;连续服药5d后,3组受试者最高心率分别下降(21.27±4.32)次/min、(26.74±5.21)次/min、(55.51±6.38)次/min,最低心率(次/min)分别下降(3.60+0.78)次/min、(3.25±0.52)次/min、(3.78±0.43)次/min,平均心率分别下降(12.31±1.43)次/min、(12.34±1.29)次/min、(20.32±2.78)次/min,总心搏次数分别下降(9838.46±900.42)次、(11345.27±1213.54)次、(25461.46±2746.78)次。所有受试者服药后QTc间期均较服药前缩短,且有时间及剂量依赖性。光幻视是最常见的不良事件。结论在5—20mg剂量范围,盐酸伊伐布雷定的耐受性良好,并可以减慢中国健康受试者心率,缩短QTc间期。 Objective To evaluate the impact of hydrochloride ivahradine on the heart rate and QTc interval after single and multiple doses in healthy Chinese volunteers. Methods Thirty-six volunteers were randomized into three groups :ivabadine 5 mg group ( n = 12, group 1 ), 10 mg group ( n = 12, group 2 ) and 20 mg group ( n = 12, group3). Each volunteer received single dose of ivabradine on day 1 and day 8, and was given ivabradine twice daily from day 3 to day 7. Results Resting heart rate was reduced from (62. 67 ±5.68 ) bpm to (59. 75 ±6. 52)bpm in group l, (67. 00 ± 7. 11 ) bpm to (62. 75±8. 35 ) bpm in group2, (59. 75 ± 6. 52 ) bpm to (56. 50±3.92)bpm in group3 at 2 hours after single dose administration and back to baseline after 6 hours. After 5 days continuous medication,the maximum heart rate (21.27-4. 32)bpm, (26. 74±5.21 )bpm and ( 55.51 ±6. 38 ) bpm in 3 groups respectively, the minimum heart rate was lowered ( 3.60 ±0. 78 ) bpm, ( 3.25 ± 0. 52)bpm and (3. 78±0. 43 ) bpm, the average heart rate was lowered ( 12. 31 ± 1.43 ) bpm, ( 12. 34± 1.29 ) bpm and (20. 32±2. 78 )bpm, the total heart rate was reduced (9838.46±900. 42)bpm, ( 11345.27± 1213. 54)bpm and (25461.46±2746.78) bpm. The QTe interval was decreased and demonstrated timeand dosedependent. Phosphene-like mild transient visual symptoms were the most frequently reported adverse events. Conclusion Ivabradine at the doses of 5 mg to 20 mg bid was well tolerated and could decrease resting heart rate and QTc interval in healthy Chinese volunteers.
出处 《中华心律失常学杂志》 2013年第2期91-94,共4页 Chinese Journal of Cardiac Arrhythmias
基金 基金项目:重大新药创制“科技重大专项”(2012ZX09303008) 国家“十一五”科技重大专项(2008ZX09312-018)
关键词 盐酸伊伐布雷定 心率 QTC间期 Hydrochloride ivabradine Heart rate QTc interval
  • 相关文献

参考文献6

  • 1Fox K,Ferrari R,Tendera M,et al. Rationale and design of a ran-domized ,double-blind, placebo-controlled trial of ivabradine in pa-tients with stable coronary artery disease and left ventricular systol-ic dysfunction : the morbidity-mortality evaluation of the If inhibitorivabradine in patients with coronary disease and left ventriculardysfunction ( BEAUTIFUL) study. American Heart Journal ,2006 ,152:860-866.
  • 2Fox K,Ford I, Steg PG, et al. Ivabradine for patients with stablecoronary artery disease and left ventricular systolic dysfunction(BEAUTIFUL ) : a randomised,double-blind,placebo controlledtrial. Lancet,2008,372:807-816.
  • 3Karl S, Michel K, Michael B, et al. Ivabradine and outcomes inchronic heart failure ( SHIFT) : a randomized placebo-controlledstudy. Lancet ,2010,376 :875-885.
  • 4Mona R,Mazen T,Ali A,et ai. Ivabradine,a novel rate slower.:Isit a sword of double blades in patients with idiopathic dilated car-diomyopathy. Anadolu Kardiylo Derg,2011 ,11 :402-406.
  • 5Lorenzo LB, Slabomira F, Ramon M, et al. Long-term safety anddfficacy of Ivabradine in patients with chronic stable angina. Car-diology ,2007 ,108 :387-396.
  • 6Camm AJ,Lau CP, Electrophysiological effects of a single intrave-nous administration of ivabradine in adult patients with normalbaseline electrophysiology. Drugs R D,2003 ,4 :83-89.

同被引文献42

  • 1无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2190
  • 2Riccioni G.Ivabradine:frommolecular basis to clinical effectiveness[J].Adv Ther,2010,27(3):160-167.
  • 3Lappegard KT.Ivabradine and nightmares:apreviously unreported adverse reaction[J].Eur J Clin Pharmacd,2009,11(suppl D):D19-D27.
  • 4Savelieva I,Camm AJ.If inhibition with ivabradine:electrophysiological effects and safety[J].Drug Saf,2008,31(2):95.
  • 5European Public Assessment Report(EPAR):Scientific discussion for Procoralan.London:EMEA,2005.
  • 6Hansson GK.Mechanlsms of disease:inflammation,atherosclerosis,and coronary artery disease[J].N Engl J Med,2005,352(16):1626-1685.
  • 7Heller EA,Lin E,et al.Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells[J].Circulation,2006,113(19):2301.
  • 8Thomas W,Peter B,Dusica V,et al.Ivabradine reduces chemokinc-induced CD4-positive Lymphocyte migration[J].Mediators Inflamm,2010,2010:751313.
  • 9Vaillant F,Timour Q,Descotes J.Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia:an experimental study[J].J Cardiovase Pharmacol,2008,52:548-554.
  • 10Tardif JC,Ponikowski P,Kahan T,et al.Efficacy of the I(f)cursent inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy:a 4 month,randomized,placebo-controlled trial[J].Eur Heart J,2009,30(5):540-548.

引证文献5

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部